Literature DB >> 2408905

Major surface protein of Toxoplasma gondii (p30) contains an immunodominant region with repetitive epitopes.

C Rodriguez, D Afchain, A Capron, C Dissous, F Santoro.   

Abstract

Four monoclonal antibodies (mAb) against surface antigens of tachyzoites of Toxoplasma gondii were produced. Immunoprecipitation of extracts of 125I-labeled tachyzoites identified the same polypeptide with apparent molecular weight of 30 000 (p30). A competition binding assay indicated that a single region of p30 was recognized by all 4 of the mAb. Furthermore, we found that single mAb inhibited 25-50% of the specific binding of antibodies of patients with toxoplasmosis to the antigenic extract of tachyzoites. It appears, therefore, that p30 is the most immunogenic constituent of tachyzoites, and that a single region of this molecule contains most of the immunogenic activity. Finally, a two-site/one-antibody immunoradiometric assay with the same mAb indicated that the p30 molecule is multivalent with respect to the expression of a single epitope.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2408905     DOI: 10.1002/eji.1830150721

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  14 in total

1.  Molecular characterization of SerH3, a Tetrahymena thermophila gene encoding a temperature-regulated surface antigen.

Authors:  M M Tondravi; R L Willis; H D Love; G A Bannon
Journal:  Mol Cell Biol       Date:  1990-11       Impact factor: 4.272

2.  Specific binding of neoglycoproteins to Toxoplasma gondii tachyzoites.

Authors:  R Robert; P L de la Jarrige; C Mahaza; J Cottin; A Marot-Leblond; J M Senet
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

3.  Advantage of using 35,000-molecular-weight protein for testing of Toxoplasma gondii immunoglobulin M.

Authors:  P Deletoille; G Ovlaque; B Slizewicz
Journal:  J Clin Microbiol       Date:  1988-04       Impact factor: 5.948

4.  Use of monoclonal antibodies in an ELISA to detect IgM class antibodies specific for Toxoplasma gondii.

Authors:  A H Balfour; J P Harford; M Goodall
Journal:  J Clin Pathol       Date:  1987-08       Impact factor: 3.411

5.  Demonstration of immunoglobulin M class antibodies to Toxoplasma gondii antigenic component p35000 by enzyme-linked antigen immunosorbent assay.

Authors:  E G Lindenschmidt
Journal:  J Clin Microbiol       Date:  1986-12       Impact factor: 5.948

6.  Toxoplasma gondii: redistribution of tachyzoite surface protein during host cell invasion and intracellular development.

Authors:  J Grimwood; J E Smith
Journal:  Parasitol Res       Date:  1995       Impact factor: 2.289

7.  Recombinant Toxoplasma gondii surface antigen 1 (P30) expressed in Escherichia coli is recognized by human Toxoplasma-specific immunoglobulin M (IgM) and IgG antibodies.

Authors:  D Harning; J Spenter; A Metsis; J Vuust; E Petersen
Journal:  Clin Diagn Lab Immunol       Date:  1996-05

8.  Discovery of compounds blocking the proliferation of Toxoplasma gondii and Plasmodium falciparum in a chemical space based on piperidinyl-benzimidazolone analogs.

Authors:  Nadia Saïdani; Cyrille Y Botté; Michael Deligny; Anne-Laure Bonneau; Janette Reader; Ronald Lasselin; Goulven Merer; Alisson Niepceron; Fabien Brossier; Jean-Christophe Cintrat; Bernard Rousseau; Lyn-Marie Birkholtz; Marie-France Cesbron-Delauw; Jean-François Dubremetz; Corinne Mercier; Henri Vial; Roman Lopez; Eric Maréchal
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

9.  Production and characterization of monoclonal antibodies directed against Eimeria falciformis and cross-reactive with sporozoites from two species of avian coccidia.

Authors:  M Kazanji; A Rhalem; P Péry
Journal:  Parasitol Res       Date:  1994       Impact factor: 2.289

10.  Serodiagnosis of toxoplasma infection using a purified parasite protein (P30).

Authors:  F Santoro; D Afchain; R Pierce; J Y Cesbron; G Ovlaque; A Capron
Journal:  Clin Exp Immunol       Date:  1985-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.